Sign up Australia
Proactive Investors - Run By Investors For Investors

AtCor Medical signs $1 million contract with international pharmaceutical company

This contract is a validation of AtCor’s technology in trials for the treatment of heart failure.
heart shape
Heart failure costs over US$30 billion annually in the U.S.

Atcor Medical Holdings Limited (ASX:ACG) has signed a $1 million contract to supply its SphygmoCor® systems and clinical trial support services to a major international pharmaceutical company.

Central arterial pressure waveform analysis, as measured by the SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions.

New contract expected to open up more opportunities for AtCor

The international pharmaceutical company is a new client for AtCor. The clinical trial is in the treatment of heart failure and will be conducted across several European sites.

It is a phase II trial which, if successful, is expected to open a larger opportunity for AtCor.  The trial will run for 18-24 months and the majority of revenue will be recognised in FY2019.

This contract is further validation of AtCor’s core technology in large pharmaceutical trials for the treatment of heart failure and related disorders.

Heart failure is a costly disease

Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood through to meet the body's needs for blood and oxygen.

In the U.S. alone, circa 5.7 million people have heart failure at a total economic cost of over US$30 billion per annum.

There is increasing interest in utilising SphygmoCor in heart failure trials and in the clinic.

This is the second heart failure trial using SphygmoCor to commence in the past 6 months and discussions are underway for additional trials.

More than 4,000 SphygmoCor systems are currently in use worldwide at major medical institutions, doctors’ offices, research institutions and in various clinical trials.

View full ACG profile View Profile

Atcor Medical Holdings Ltd Timeline

Newswire
June 15 2015
Newswire
January 22 2015

Related Articles

1530537220_Blood-Test.jpg
July 03 2018
The research and diagnostic company develops cancer-detecting blood tests
1521490126_shutterstock_234586750.jpg
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc
1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use